A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

NCT06954961 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

640

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: D-0502
DRUG: Fulvestrant

Sponsor

InventisBio Co., Ltd